Related Experiment Videos
[Ischemic hepatitis in patients with heart failure]
J Muñoz-Rodríguez1, J M Tricas Leris, V Andreu Solsona
1Servicio de Medicina Interna, Hospital de Mollet, Mollet del Vallès, Barcelona, Spain. 28587fmr@comb.es
Anales De Medicina Interna (Madrid, Spain : 1984)
|November 20, 2003
Summary
Ischemic hepatitis, marked by elevated liver enzymes, occurs when hepatic blood flow is reduced, often in heart failure patients. Diagnosis requires excluding other hepatitis causes, with centrilobular necrosis as a key feature.
Area of Science:
- Hepatology
- Cardiology
- Pathology
Background:
- Ischemic hepatitis presents as reversible elevation of liver enzymes (AST, ALT) due to reduced hepatic blood flow.
- It is frequently observed in patients with underlying heart failure.
- Diagnosis necessitates excluding other causes of hepatitis, such as viral infections and drug toxicity.
Observation:
- This study details three cases of ischemic hepatitis encountered within a single year.
- These cases were identified within the medical service of the reporting institution.
- The study period covered one year of patient admissions.
Findings:
- Ischemic hepatitis was diagnosed in 2.7% of all heart failure patients admitted during the study period.
- Centrilobular necrosis was identified as the primary histologic finding in these cases.
- The observed cases highlight the clinical relevance of ischemic hepatitis in heart failure management.
Implications:
- Early recognition of ischemic hepatitis is crucial for managing patients with heart failure.
- Understanding the prevalence and characteristics of ischemic hepatitis can improve patient outcomes.
- Further research into the mechanisms and treatment of ischemic hepatitis in cardiac patients is warranted.